Use of bisphosphonates as HIV/AIDS adjunctive treatment
US9820998B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 15, 2015 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | Jun 26, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5153
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.